Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.21756 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses.
Cell Rep
December 2024
Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON M5G 1L7, Canada. Electronic address:
Interleukin-10 (IL-10)-producing group 2 innate lymphoid cells (ILC2) regulate inflammatory immune responses, yet their therapeutic potential remains largely unexplored. Here, we demonstrate that cell therapy with human ILC2 inhibits pathogenic T cell responses in humanized mouse models of graft-versus-host disease (GVHD), resulting in reduced GVHD severity and improved overall survival without limiting the graft-versus-leukemia effect. ILC2 conferred superior protection from GVHD than IL-10 ILC2s, and blocking IL-10 and IL-4 abrogated ILC2 protective effects, indicating that these cytokines are important for the protective effects of ILC2.
View Article and Find Full Text PDFCell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy.
Sci Rep
November 2024
Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Article Synopsis
- Multiple myeloma (MM) is a type of cancer that starts in plasma cells and is divided into two main genetic subtypes: hyperdiploid and non-hyperdiploid.
- This study used human myeloma cell lines (HMCLs) to investigate protein expression of cell surface markers relevant to MM treatment, finding that some markers were consistently expressed while others showed variation.
- Analysis revealed that some HMCLs closely matched the characteristics of patient-derived samples, highlighting the need for careful selection of cell lines to best model MM for research and therapeutic purposes.
Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens.
J Vis Exp
September 2024
Institute for Laboratory Medicine and Microbiology, University Hospital Augsburg.
Rapid and resource-efficient sample processing, high throughput, and high robustness are critical for effective scientific and clinical application of advanced antigen-specific immunoassays. Traditionally, such immunoassays, especially antigen-specific T-cell analysis by flow cytometry or enzyme-linked immunosorbent spot assays, often rely on the isolation of peripheral blood mononuclear cells. This process is time-consuming, subject to many pre-analytic confounders, and requires large blood volumes.
View Article and Find Full Text PDFThe Application of Mesenchymal Stem Cells in Different Cardiovascular Disorders: Ways of Administration, and the Effectors.
Stem Cell Rev Rep
October 2024
Physiology, Department of Basic Medical Sciences, Medicine Faculty, Selcuk University, Konya, Türkiye.
The heart is an organ with a low ability to renew and repair itself. MSCs have cell surface markers such as CD45, CD34, CD31, CD4, CD11a, CD11b, CD15, CD18, CD25, CD49d, CD50, CD105, CD73, CD90, CD9, CD10, CD106, CD109, CD127, CD120a, CD120b, CD124, CD126, CD140a, CD140b, adherent properties and the ability to differentiate into cells such as adipocytes, osteoblasts and chondrocytes. Autogenic, allogeneic, normal, pretreated and genetically modified MSCs and secretomes are used in preclinical and clinical studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!